Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal
Merck KGaA is bowing out of the CAR-T development business, handing over its rights to Intrexon $XON in exchange for $150 million batch of stock.
The German Merck is characterizing the move as an R&D simplification process, staying focused where they believe they can make the most progress. And the deal comes three years after the two companies allied on CAR-T, with Intrexon contributing its tech — including Sleeping Beauty — for the preclinical work underway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.